Table 1.
Expression of phospho-S6rp and – 4E-BP1 at various stages of CTCL
| S6rp S235/236 | 4E-BP1 S65 | |
|---|---|---|
| Patch stage | ||
| 0% to 25% | 9 (100)* | 9 (100) |
| 26% to 50% | 0 (0) | 0 (0) |
| More than 50% | 0 (0) | 0 (0) |
| Plaque stage | ||
| 0% to 25% | 8 (80) | 9 (90) |
| 26% to 50% | 2 (20) | 1 (10) |
| More than 50% | 0 (0) | 0 (0) |
| Tumor stage | ||
| 0% to 25% | 2 (33) | 1 (17) |
| 26% to 50% | 4 (67) | 5 (83) |
| More than 50% | 0 (0) | 0 (0) |
| Lymph node | ||
| 0% to 25% | 1 (10) | 2 (20) |
| 26% to 50% | 6 (60) | 7 (70) |
| More than 50% | 3 (30) | 1 (10) |
| Large cell transformation | ||
| 0% to 25% | 0 (0) | 0 (0) |
| 26% to 50% | 3 (60) | 4 (80) |
| More than 50% | 2 (40) | 1 (20) |
Skin biopsies from the patch, plaque, and tumor stages and the involved lymph nodes were stained by immunohistochemistry for the above-mentioned proteins. The cases are grouped based on the depicted percentage of staining of the atypical lymphocytes. Values are number of cases within the group; percentage of cases within the given CTCL stage in parentheses.